ReviewRheumatology international2009
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.
Review in Rheumatology international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 34 citations in OpenAlex.
- Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept.Rheumatology international · 2013Trial
- Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.British journal of clinical pharmacology · 2012Trial
- The Relationship between the Occipitocervical Junction and Thoracic Kyphosis in Ankylosing Spondylitis: A Retrospective Cohort Study of 86 Cervical Fractures in Surgically Treated Patients.Asian spine journal · 2019Article
- Geographic Variation in Diagnostic Ability and Quality of Care Metrics: A Case Study of Ankylosing Spondylitis and Low Back Pain.Inquiry : a journal of medical care organization, provision and financing · 2017Article
- Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.Rheumatology international · 2015Observational
- Increased occurrence of spinal fractures related to ankylosing spondylitis: a prospective 22-year cohort study in 17,764 patients from a national registry in Sweden.Patient safety in surgery · 2013Article
- Epigenetics and the transition from acute to chronic pain.Pain medicine (Malden, Mass.) · 2012Review
- The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis.Clinical rheumatology · 2010Article
- Pathogenesis of ankylosing spondylitis.Nature reviews. Rheumatology · 2010Review
- The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.Arthritis research & therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disorder involving the sacroiliac joints (SIJs), spine and less frequently the peripheral joints. Traditionally, it is well recognised that AS is a challenging disease to manage due to the lack of effective therapeutic options. Current evidence would suggest this has changed and there are now a number of therapies available that provide persistent control of inflammatory symptoms with improvement in daily function. NSAIDs remain the first step in patient treatment. Sulphasalazine may be effective in peripheral arthritis and there are emerging data to support its use in early inflammatory back pain. Studies have shown that pamidronate and steroid injection into SIJ have a symptom-modifying effect in AS. Current data suggest that anti-TNF treatment promises early benefit which is likely to continue in the longer term. Treatment with biologics should be considered sooner rather than later in the management of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.